Brand, Toni M <br/><br/>
AXL mediates resistance to cetuximab therapy.  [electronic resource] 

 -  Cancer research  Sep 2014 
 - 5152-64 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1538-7445 
<br/><br/><label>Standard No.: </label>10.1158/0008-5472.CAN-14-0294  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal, Humanized--pharmacology<br/>Antineoplastic Agents--pharmacology<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Carcinoma, Squamous Cell--drug therapy<br/>Cell Growth Processes--drug effects<br/>Cell Line, Tumor<br/>Cetuximab<br/>Drug Resistance, Neoplasm<br/>Head and Neck Neoplasms--drug therapy<br/>Humans<br/>Lung Neoplasms--pathology<br/>Mice<br/>Mice, Nude<br/>Proto-Oncogene Proteins--biosynthesis<br/>RNA, Small Interfering--administration & dosage<br/>Receptor Protein-Tyrosine Kinases--biosynthesis<br/>Squamous Cell Carcinoma of Head and Neck<br/>Transfection<br/>Xenograft Model Antitumor Assays<br/>Axl Receptor Tyrosine Kinase